Waller D G, Waller D
Br J Rheumatol. 1984 Feb;23(1):24-5. doi: 10.1093/rheumatology/23.1.24.
We report a case of hypoglycaemia due to a 'first-dose' interaction between azapropazone and tolbutamide. The mechanism was probably by displacement of tolbutamide from protein binding sites, and it is recommended that azapropazone should be avoided in patients receiving tolbutamide.
我们报告了一例因阿扎丙宗与甲苯磺丁脲之间的“首剂”相互作用导致低血糖的病例。其机制可能是阿扎丙宗从蛋白质结合位点置换了甲苯磺丁脲，建议接受甲苯磺丁脲治疗的患者避免使用阿扎丙宗。
